Sign inCreate account

Report workspace tools

NCT02435147COMPLETEDanonymous

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Sponsor

Source record

HealthEast Care System

Phase

Source record

Completed

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

denosumab

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

denosumab

Source & freshness

Source record

NCT ID

NCT02435147

Original source

ClinicalTrials.gov

Source last updated

Oct 29, 2018

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02435147

Title

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Sponsor

HealthEast Care System

Status

COMPLETED

Phase

Completed

Condition raw

Osteoporosis, Bone Fracture

Condition normalized

Osteoporosis, Bone Fracture

Modality raw

small molecule

Modality normalized

monoclonal antibody

Target raw

denosumab

Target normalized

denosumab

Interventions

denosumab

Public preview

Source record

This study evaluated the long-term effects of denosumab on trabecular bone score (TBS) and femur strength index (FSI) in postmenopausal women with osteoporosis. Conducted by HealthEast Care System, the observational study involved 86 participants, with 75 completing the study. The findings support denosumab's role in improving bone health metrics over 36 months.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02435147

Status

COMPLETED

Phase

Completed

Sponsor

HealthEast Care System

Executive brief

Investment-Ready Snapshot

This study evaluated the long-term effects of denosumab on trabecular bone score (TBS) and femur strength index (FSI) in postmenopausal women with osteoporosis. Conducted by HealthEast Care System, the observational study involved 86 participants, with 75 completing the study. The findings support denosumab's role in improving bone health metrics over 36 months.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 29, 2018
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02435147

Indication

Osteoporosis

Modality

monoclonal antibody

Target

denosumab

Intervention

denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.